Obagi Medical and It's a Secret Med Spa Announce Collaboration in the ALOHA Program to Drive Real-World Evidence for Obagi® saypha® MagIQ(TM)
MWN-AI** Summary
Obagi Medical, a leader in physician-dispensed skincare and part of Waldencast plc (NASDAQ: WALD), has announced a collaboration with It’s a Secret Med Spa as part of the ALOHA (Aesthetics Leadership with Obagi’s Hyaluronic Acid) Program. This partnership aims to generate real-world data to validate the clinical safety and efficacy of Obagi’s saypha® MagIQ™ injectable, which has demonstrated impressive results in FDA pivotal trials.
The collaboration will allow It’s a Secret Med Spa to leverage its clinical expertise and luxury patient experience to assess how the clinical data translates into everyday practice across multiple locations. Garret Gay, Vice President of Sales at It’s a Secret Med Spa, emphasized that the partnership aligns perfectly with their commitment to providing an exceptional aesthetic experience and integrates the best of Obagi’s advanced protocols.
The ALOHA Program incorporates a real-world clinical initiative and structured evaluations, providing It’s a Secret Med Spa's providers with hands-on experience in using the saypha® MagIQ™ product. This initiative seeks to enhance patient satisfaction and fortify the relationships between clients and providers. Drew Fine, U.S. General Manager for the Professional Channel at Obagi, highlighted that the collaboration underscores the commitment to launching the injectable based on robust clinical evidence, emphasizing education and patient outcomes.
Obagi’s saypha® MagIQ™, developed by Croma-Pharma GmbH, employs proprietary MACRO Core Technology for high-performance, natural-looking results, and has quickly gained recognition in the competitive professional skincare market. With Obagi Medical's legacy of over 35 years in the industry, the collaboration with It’s a Secret Med Spa is poised to elevate standards across premium med spa practices, enhancing the overall aesthetic treatment experience for clients.
MWN-AI** Analysis
The recent collaboration between Obagi Medical and It’s a Secret Med Spa in their ALOHA Program marks a significant development in the aesthetics market, positioning both entities to leverage real-world evidence for the innovative saypha® MagIQ™ injectable. This partnership aligns with Obagi's commitment to robust clinical validation and excellence in patient care, enhancing its reputation as a leading player in physician-dispensed skincare.
Investors should monitor this collaboration closely, as the ALOHA Program promises to yield critical insights into the product's real-world efficacy, potentially driving increased consumer confidence and adoption rates. By integrating high-performance clinical expertise from It’s a Secret Med Spa, renowned for its luxury patient experience and advanced aesthetic treatments, Obagi stands to amplify its reach and impact, particularly within the fast-growing premium med spa sector.
The strategic focus on evidence-based practices may attract discerning clients who prioritize quality and proven results in their aesthetic treatments. Additionally, with Obagi being recognized as the fastest-growing professional skincare brand in the U.S. as of 2024, there is substantial growth potential. The involvement of It’s a Secret, the largest provider of neurotoxins and dermal fillers in Texas, further strengthens Obagi’s market penetration and distribution capabilities.
Moreover, the proprietary MACRO Core Technology behind saypha® MagIQ™, which ensures natural-looking results and effective deliverability, adds a competitive edge. As the market continues to trend towards personalized aesthetic solutions, the collaboration could position Obagi favorably against competitors.
In summary, this partnership is a compelling growth story for investors. Keep an eye on the data emerging from the ALOHA Program and consumer reception to the new injectable. Positive outcomes could enhance Obagi's market standing and financial performance, making it a stock worth considering for those focused on the beauty and wellness sectors.
**MWN-AI Summary and Analysis is based on asking OpenAI to summarize and analyze this news release.
NEW YORK and DALLAS, Feb. 25, 2026 (GLOBE NEWSWIRE) -- Obagi Medical, a leading innovator in physician-dispensed skincare and aesthetic solutions and part of Waldencast plc (NASDAQ: WALD) (“Waldencast” or the “Company”), today announced It’s a Secret Med Spa as a key partner in the Aesthetics Leadership with Obagi’s Hyaluronic Acid (ALOHA) Program. It’s a Secret Med Spa will help generate real-world data to translate the clinical safety and efficacy demonstrated in FDA pivotal trials into everyday practice across multiple locations and structured evaluation programs.
“This partnership with Obagi makes perfect sense for us. They’re taking a thoughtful, evidence-based approach to launching this innovative injectable, and we have the clinical expertise, luxury patient experience, and high-performance environment to evaluate how trial data performs in real-world premium med spa settings,” said Garret Gay, Vice President of Sales at It’s a Secret Med Spa. “Our providers deliver advanced aesthetic treatments every day to discerning clients who expect the absolute best in results, service, and atmosphere. That elevated experience matters. The ALOHA Program is an ideal fit for premium, high-touch med spas like ours — giving us access to best-in-class protocols, real-world insights, and the ability to integrate saypha® MagIQ™ with the complete Obagi ecosystem to deliver exceptional outcomes for our clients.”
The ALOHA Real-World Program is designed to give It’s a Secret Med Spa providers hands-on experience with Obagi saypha® MagIQ™ while evaluating complete Obagi protocols. This approach aims to drive patient satisfaction and strengthen relationships between clients and their providers. The program includes a real-world clinical initiative supplemented by a structured evaluation process across participating It’s a Secret Med Spa locations, with standardized data capture.
“Partnering with It’s a Secret Med Spa is a clear statement of our intent to launch this new injectable on a foundation of robust clinical evidence, education, and integrated patient outcomes,” said Drew Fine, U.S. General Manager, Professional Channel. “The ALOHA collaboration with It’s a Secret brings together luxury clinical expertise, exceptional patient experience, and a shared passion for delivering extraordinary results — reinforcing Obagi’s commitment to supporting high-performing practices of all models and helping elevate the standard of care across the premium med spa landscape.”
Obagi® saypha® MagIQ™, developed by Croma-Pharma GmbH, utilizes proprietary MACRO Core Technology to create a stable three-dimensional hyaluronic acid matrix. The technology is designed to deliver natural-looking results with category-leading performance, including high usable HA content upon injection, consistent gel distribution, and a predictable injection force and swelling profile¹.
For more information about ALOHA, visit https://obagi-professional.com.
About Obagi Medical
Obagi Medical is an industry-leading, advanced skincare line rooted in research and skin biology, with a legacy of 35+ years of experience. Initially known for its leadership in the treatment of hyperpigmentation with the Obagi Nu-Derm® System, Obagi Medical products are designed to address a variety of skin concerns, including premature aging, photodamage, skin discoloration, acne, and sun damage. As the fastest-growing professional skincare brand in the U.S. in 2024,² Obagi Medical empowers individuals to achieve healthy, beautiful skin. More information about Obagi Medical is available on the brand's website, https://www.obagi.com.
About It’s a Secret Med Spa
It’s a Secret Med Spa is a premier luxury medical spa experience offering the most advanced aesthetic treatments in a sophisticated and highly personalized environment. Specializing in injectables, laser treatments, skin rejuvenation, and wellness services, It’s a Secret is the largest provider of neurotoxins, dermal fillers, and injectable medical aesthetics in Texas & the Southwestern United States. Known for exceptional results, white-glove service, and an uncompromising focus on client satisfaction. With 15 high-end locations and a growing national presence, It’s a Secret Med Spa delivers elite-level care to clients who demand the very best. For more information, visit https://secretmedspa.com.
About Waldencast plc
Founded by Michel Brousset and Hind Sebti, Waldencast’s ambition is to build a global best-in-class beauty and wellness operating platform by developing, acquiring, accelerating, and scaling conscious, high-growth purpose-driven brands. Waldencast’s vision is fundamentally underpinned by its brand-led business model that ensures proximity to its customers, business agility, and market responsiveness, while maintaining each brand’s distinct DNA. For more information please visit: https://ir.waldencast.com.
Media Contact:
obagi@behrmancesa.com
Source: Waldencast plc
¹ Puljic A, Frank K, Cohen J, Otto K, Mayr J, Hugh-Bloch A, Kuroki-Hasenöhrl, D. A Scientific Framework for Comparing Hyaluronic Acid Filler Crosslinking Technologies. Gels. 2025; 11(7):487
² Among the Top 10 Professional Skin Care Brands in the U.S., According to Kline’s 2024 Global Professional Skin Care Series (China, Europe and the U.S.)
FAQ**
How does the partnership between It’s a Secret Med Spa and Waldencast Acquisition Corp. WALD aim to enhance the clinical evaluation of Obagi’s saypha® MagIQ™ in New York and Dallas?
In what ways might the ALOHA Program impact client satisfaction at It’s a Secret Med Spa locations in New York and Dallas under Waldencast Acquisition Corp. WALD’s guidance?
How does the luxury patient experience at It’s a Secret Med Spa align with Waldencast Acquisition Corp. WALD’s strategy for the ALOHA Program in both New York and Dallas?
What are the anticipated outcomes of the collaboration between Waldencast Acquisition Corp. WALD and It’s a Secret Med Spa in enhancing the standards of care across these cities?
**MWN-AI FAQ is based on asking OpenAI questions about Waldencast Acquisition Corp. (NASDAQ: WALD).
NASDAQ: WALD
WALD Trading
-4.69% G/L:
$1.525 Last:
13,064 Volume:
$1.51 Open:
